Belite Bio (BLTE) Stock Analysis & Forecast

Nov 13 close

$164.36−5.60 (−3.3%)

Gekko Brief

Nov 9 close

Belite Bio closed at $157.69 on 9 November 2026, +2.3% on the day. The price sits between the 50-day ($160.83) and 200-day ($160.20) moving averages, inside a 52-week range of $102.00 to $200.00. The GekkoIndex reads 57.3, in the Neutral zone, down 2.7 points over five sessions. Gekko Fair Value is $172.40, so the price is 8.5% below it.

The next earnings report is due on 12 November 2026, 106 days away. Over the last 8 reports the company beat the earnings estimate 2 times, with an average move of 5% across the report. Seasonally, the next 20 trading days from this point averaged +8.7% over the last 4 years, rising in 3 of them.

7 firms rate the stock: 7 buy, 0 hold and 0 sell, with a consensus target of $227.44. A typical daily move is about 4.3%, and a typical 20-day move about 10.1%. On the swing-trade checklist, 2 items read supportive and 1 reads as a headwind (earnings risk).

A plain summary of the figures as of the Nov 9, 2026 close.

Belite Bio price vs fair value

$174.40$164.36Nov ’25May ’26Nov ’26
Close $164.36200-day averageGekko Fair Value $174.40

Belite Bio quick facts

Market cap
$6.62B
P/E ratio
—
Forward P/E
416.7
EPS, TTM
−$2.74
Revenue, TTM
$0
Profit margin
0%
Dividend yield
—
Beta
-1.19
Volume
216,975 avg 174,107
1-year return
+48.3%
Typical daily move
±5.2%
Typical 20-day move
±10.1%
50-day average
$160.88
200-day average
$160.11
Next earnings
Mar 1
Shares outstanding
40.27M
52-week range
$105.88$200.00

Belite Bio swing-trade checklist

Belite Bio scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive1 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $164.36 is above the 50-day ($160.88) and 200-day ($160.11) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    52.2, Neutral

    Reading 52.2 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    5.8% below

    Price is 5.8% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 106 days

    Next report Mar 1, 2027, 106 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +8.1% on average

    From this point in the calendar, the next 20 trading days averaged +8.1% over 4 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Belite Bio stock chart and price history

Belite Bio closed at $164.36 on Nov 13, 2026, +48.3% over the past year, inside a 52-week range of $105.88 to $200.00.

Close50-day average200-day averageVolume
Belite Bio share price, past year, with 50-day and 200-day moving averages and volume$75$100$125$150$175$200DecJan 2026FebMarAprMayJunJulAugSepOctNov164.36

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+7.7%
3 months
+0.7%
6 months
+14.9%
1 year
+48.3%
The full BLTE chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BLTE in Gekko

Follow Belite Bio through every session

Put BLTE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track BLTE in GekkoFree for 7 days. No credit card required.

About Belite Bio

Belite Bio is a clinical-stage biopharmaceutical company that works on developing treatments still in the testing stages, rather than products already on the market. Much of its research centers on eye disorders, particularly atrophic age-related macular degeneration and a form of Stargardt disease that runs in families. Its best-known program is LBS-008, an oral drug taken once a day that is now in Phase 3 trials and is meant to control how vitamin A moves to the eye, limiting the buildup of certain vitamin A byproducts that can damage eye tissue.

The company also has a second program, LBS-009, which is being studied in earlier, preclinical stages. This candidate works by blocking retinol binding protein 4 and is intended for liver-related conditions such as fatty liver disease, steatohepatitis, and type 2 diabetes. Belite Bio functions as part of Lin Bioscience International Ltd.

Belite Bio was started in 2016 and has its main offices in San Diego, California. Its stock trades under the ticker BLTE.

Sector
Health technology
Website
belitebio.com

Belite Bio GekkoIndex: the smart money zone

Belite Bio’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 52.2, in the Neutral zone, down 7.9 points over five sessions.

010052.2Neutral

Down 7.9 points over five sessions, from the Accumulation zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying25+2.7%+1.1%+3.6%+18.4%
Accumulation182+1.0%+1.9%+5.0%+8.8%
Neutral (current zone)355+1.2%+2.5%+4.8%+18.4%
Distribution87+1.1%+2.9%+7.9%+12.7%
Selling6Too few readings yet

Average BLTE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the BLTE price, zone by zone.Track BLTE in Gekko

Is Belite Bio stock overvalued? Gekko Fair Value

Belite Bio trades 5.8% below Gekko Fair Value of $174.40, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Belite Bio shares are worth, recalculated every trading day.

$174.40

Gekko Fair Value, Nov 14, 2026

5.8% Undervalued

At the end of Aug 2026 the price was 21.7% below the estimate.

Gekko Fair ValueShare price, month end
$174$164Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open BLTE in Gekko

Belite Bio insider and Congress trading

No open-market insider purchases were filed for Belite Bio, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for BLTE in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every BLTE insider filing, plotted on the chart in Gekko.Open BLTE in Gekko

Congress trades last 90 days

No trades in BLTE were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for BLTE, plotted on the chart in Gekko.Open BLTE in Gekko

Hedge funds and billionaires quarter ended Mar 31

1of the funds Gekko tracks holds BLTE.

0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko

Belite Bio earnings: next date and track record

Belite Bio reports on Mar 1, 2027 (106 days away), and beat the EPS estimate in 3 of its last 8 reports.

3 of 8reports beat the EPS estimate
±5.4%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

+4.6%Nov ’24−0.6%May ’25+4.1%Aug ’25−6.6%Nov ’25−11.8%Mar ’26+3.3%May ’26−6.4%Aug ’26+5.4%Nov ’26
ReportedEPSSurpriseRevenueSurpriseMove
Nov 12, 2026−$0.60
est −$0.79
+23.7%——+5.4%
Aug 12, 2026−$0.70
est −$0.73
+4.1%——−6.4%
May 20, 2026−$0.68
est −$0.64
−6.3%—
est $16.67M
—+3.3%
Mar 2, 2026−$0.70
est −$0.54
−29.6%—
est $16.67M
—−11.8%
Nov 10, 2025−$0.65
est −$0.49
−32.7%——−6.6%
Aug 11, 2025−$0.50
est −$0.47
−6.4%——+4.1%
May 13, 2025−$0.45
est −$0.36
−25.0%——−0.6%
Nov 12, 2024−$0.28
est −$0.29
+3.4%——+4.6%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Belite Bio stock forecast and analyst price targets

Analysts’ average 12-month price target for Belite Bio is $230.78, +40.4% from the last close, from 5 firms rating the stock in the last 90 days.

$230.78consensus 12-month target, +40.4% from the last close
Low $200High $303
Buy5
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 5 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13Leerink PartnersBuy, maintained$215+30.8%
Nov 13H.C. WainwrightBuy, reiterated$245+49.1%
Oct 15H.C. WainwrightBuy, reiterated$245+49.1%
Sep 9Mizuho SecuritiesBuy, maintained$234+42.4%
Sep 9H.C. WainwrightBuy, reiterated$245+49.1%
+4.8%average 20-day move after past Neutral readings
+8.1%average move over the next 20 trading days in the last 4 years
±5.2%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Belite Bio seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Belite Bio averaged +8.1% across the last 4 years, rising in 3 of them.

Next 20 trading days, by year

+16.4%2022+16.7%2023−25.5%2024+22.1%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+4.9%3 of 4
Next 10 trading days+10.6%3 of 4
Next 15 trading days+10.6%3 of 4
Next 20 trading days+8.1%3 of 4
Next 30 trading days+12.6%3 of 4

For scale, BLTE’s typical 20-trading-day move in either direction is about 10.1%.

Belite Bio market cap and key statistics

Belite Bio’s market cap is $6.62B and revenue of $0 over the last twelve months.

Valuation

Market cap
$6.62B
Forward P/E
416.7
EPS, TTM
−$2.74
Gekko Fair Value
$174.40

Trading

Volume
216,975
Avg volume, 20 days
174,107
52-week high
$200.00
52-week low
$105.88
Shares outstanding
40.27M

Financials

Revenue, TTM
$0
Profit margin
0%
Return on equity
-22.1%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
-1.19
Typical daily move
±5.2%
Typical 20-day move
±10.1%

Belite Bio stock news this week

Coverage of Belite Bio this week reads positive: 5 positive, 2 neutral and 1 negative headlines.

News sentiment positive

More stocks

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Health technology

Belite Bio stock FAQ

What is Belite Bio’s market cap?

Belite Bio’s market cap is $6.62B at the Nov 13, 2026 close of $164.36, with 40.27M shares outstanding.

What is the Belite Bio stock forecast?

The consensus analyst 12-month price target for Belite Bio is $230.78, +40.4% from the last close. Of the 5 firms that rated the stock in the last 90 days, 5 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Belite Bio stock overvalued or undervalued?

On Gekko’s estimate Belite Bio is undervalued: the Nov 13, 2026 close of $164.36 is 5.8% below Gekko Fair Value of $174.40. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Belite Bio report earnings next?

Belite Bio is expected to report on Mar 1, 2027 (106 days away). Analysts expect earnings of −$0.79 per share on revenue of $25.71M. Belite Bio beat the earnings estimate in 3 of its last 8 reports, moving 5.4% on average across the report.

What is Belite Bio’s 52-week high and low?

Belite Bio’s 52-week high is $200.00 and its 52-week low is $105.88; it closed at $164.36 on Nov 13, 2026, +48.3% over the past year.

Is Belite Bio stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (trend, fair value, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Belite Bio the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.